3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
4
Polycythemia Vera
3
Myeloproliferative Disorders
3
Stomach Neoplasms
2
Cardiovascular Diseases
2
Multiple Myeloma
1
Hemorrhage
1
Gastrointestinal Neoplasms
1
Esophageal Neoplasms
1
Barrett Esophagus
1
Adenomatous Polyps
1
Adenoma
1
Interventions
Bevacizumab
9
Oxaliplatin
7
Irinotecan
6
Fluorouracil
6
Nivolumab
5
Leucovorin
5
Cetuximab
5
Capecitabine
5
pembrolizumab
4
Sunitinib
4
IFL protocol
4
Drug Therapy
4
Cisplatin
4
encorafenib
3
Pemetrexed
3
Gemcitabine
3
Folfox protocol
3
5,10-methylenetetrahydrofolic acid
3
trebananib
2
trastuzumab deruxtecan
2
amminedichloro(2-methylpyridine)platinum(II)
2
Ocoxin
2
N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
2
Levoleucovorin
2
IDRX-42
2
CGX1321
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
ulixertinib
1
tivozanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Gastrointestinal Neoplasms
×
Aspirin
×
Clear all
NCT04081831
2022-04-19
ENgAGE-HK
Bayer
Completed
99,999 enrolled